Results 161 to 170 of about 145,582 (253)

Combination Therapy with a Bispecific Antibody Targeting the hERG1/β1 Integrin Complex and Gemcitabine in Pancreatic Ductal Adenocarcinoma. [PDF]

open access: yesCancers (Basel), 2023
Lottini T   +13 more
europepmc   +1 more source

Analysis of Carbohydrates and Glycoconjugates by Matrix‐Assisted Laser Desorption/Ionization Mass Spectrometry: An Update for 2023–2024

open access: yesMass Spectrometry Reviews, EarlyView.
ABSTRACT The use of MALDI mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this comprehensive review is the twelfth update of the original article published in 1999 and brings coverage of the literature to the end of 2024.
David J. Harvey
wiley   +1 more source

Mass Spectrometry‐Based Extracellular Vesicle Proteomics for Biomarker Discovery

open access: yesMass Spectrometry Reviews, EarlyView.
ABSTRACT Extracellular vesicle (EV) proteomics has emerged as a powerful platform for decoding intercellular communication and advancing biomarker discovery across human diseases. EVs carry proteins that reflect their cells of origin, offering a minimally invasive window into physiological and pathological processes.
Ya‐Juan Liu, Juan Peng, Chao Kang
wiley   +1 more source

Allosteric regulation of fibronectin binding by the anti-β1 integrin antibody TS2/16. [PDF]

open access: yesPNAS Nexus
Ding J   +5 more
europepmc   +1 more source

Cardiac safety assessment of a novel recombinant bispecific antibody targeting the ether-à-go-go related gene 1 (hERG1)-β1 integrin macromolecular complex. [PDF]

open access: yesFront Pharmacol, 2023
Santini L   +11 more
europepmc   +1 more source

Senotherapeutics for Knee Osteoarthritis

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Osteoarthritis (OA) is a chronic disease that imposes a significant economic burden and deteriorates quality of life. Nevertheless, current therapeutic options for OA are limited to symptomatic remedies. As such, there is a high interest in novel methods for treating or preventing OA.
Ezgi Duman   +6 more
wiley   +1 more source

CLDN5 as a novel modulator of podocyte adhesion to extracellular matrix via β1-integrin binding. [PDF]

open access: yesJ Biol Chem
Wang C   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy